Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B+RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B+RIBAVIRIN IN TREATMENT-NAIVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS

Authors
Category Primary study
JournalJOURNAL OF HEPATOLOGY
Year 2010
This article has no abstract
Epistemonikos ID: e8d653118675c5d7c2cf9f662b9605782f0060c9
First added on: Feb 28, 2025